Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06088407
Other study ID # 0052-16-ASF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 21, 2016
Est. completion date September 3, 2023

Study information

Verified date October 2023
Source Assaf-Harofeh Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heterotopic ossification (HO) following elbow fracture-dislocation is a well-recognized condition that can lead to reduced range of motion, increased pain, and the necessity for repeat surgeries. Inflammation serves as a pivotal initiating factor in the formation of (HO) following a traumatic event. The inflammatory cascade triggered can lead to the dysregulation of tissue homeostasis, thereby promoting the aberrant formation of ectopic bone. Tranexamic acid (TXA), a Food and Drug Administration (FDA) approved synthetic antifibrinolytic agent, has garnered significant attention for its potential to mitigate the inflammatory response in the context of orthopaedic surgical procedures. This study aims to investigate the hypothesis that reducing soft tissue hematoma during elbow fracture-dislocation surgery through the intraoperative administration of TXA, can alleviate the occurrence or severity of ectopic bone formation. Methods: A prospective randomized study was conducted on patients with elbow fracture-dislocation who underwent surgery between 2016 and 2022. A total of 50 patients were enrolled and randomly assigned to two groups. The first group received 1 gram of intravenous tranexamic acid before the operation, followed by an additional 1 gram intravenously during wound closure. The second group did not receive any anti-bleeding medication. Patients were followed up at intervals of 2 weeks, 6 weeks, 3 months, and as needed after the surgery. At the end of the follow-up period, there were 23 patients in the first group and 24 in the second group, with a median follow-up duration of 12.7 months. All patients did not receive any other form of HO prophylaxis. Postoperative radiographs and clinical outcomes were assessed and recorded.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 3, 2023
Est. primary completion date September 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. traumatic non-pathological elbow fracture-dislocation. 2. age 18 years or older. 3. presentation within 2 weeks of injury. 4. Willingness to participate in the study Exclusion Criteria: 1. Inability to provide consent for research participation. 2. Active infection in the operated limb. 3. Previous hip fracture. 4. Head injury. 5. History of deep vein thrombosis (DVT). 6. History of venous thromboembolism (VTE). 7. Ischemic heart event within the last six months. 8. Stroke (CVA) within the last six months. 9. Coagulopathies. 10. Pregnancy.

Study Design


Intervention

Drug:
with Tranexamic acid
Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively

Locations

Country Name City State
Israel Assaf Harofeh Medical Center (Yitzhak Shamir Medical Center) Be'er Ya'aqov

Sponsors (1)

Lead Sponsor Collaborator
Assaf-Harofeh Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence of Heterotopic Ossification in plain radiographs Heterotopic Ossification presence, defined as new bone formation that had not been present in the imaging studies made at the time of the injury 2 weeks- 1 year
Secondary Functional elbow Range of motion assessment Elbow range of motion throughout the follow-up. The range of motion of the elbow was evaluated in degrees using a full circle goniometer (Jamar, Duluth, Minnesota, United States). Functional range of motion was classified as 30-130 degrees of extension-flexion according to the description by Morrey et al (A biomechanical study of normal functional elbow motion. B F Morrey, L J Askew, E Y Chao. J Bone Joint Surg Am. 1981 Jul;63(6):872-7.). Patients with worse range of motion then 30-130 degrees (larger then 30 degrees extension and lower then 130 degrees of flexion) were classified as patients with non-functional elbow range of motion. 2 weeks - 1 year
Secondary Heterotopic Ossification Classification System Score Heterotopic Ossification Classification System by Hastings and Graham (The classification and treatment of heterotopic ossification about the elbow and forearm. H Hastings 2nd, T J Graham. Hand Clin. 1994 Aug;10(3):417-37.).
The score is between I-III, where I means radiographic heterotopic ossification without elbow motion limitations (better outcome) and III means radiographic heterotopic ossification with no elbow motion (worse outcome)
2 weeks - 1 year
See also
  Status Clinical Trial Phase
Terminated NCT03724422 - HO Prophylaxis Therapy for Distal Humerus Fractures N/A
Withdrawn NCT00586365 - Naproxen for the Prevention of HO After Complex Elbow Trauma Phase 4
Enrolling by invitation NCT04867278 - Heterotopic Ossification Prophylaxis N/A
Completed NCT03925688 - Assessment of Heterotopic Ossification of Elbow Joint in Relation of Serum Uric Acid.
Recruiting NCT04934332 - Early Ultrasound Screening of Heterotopic Ossification After Severe Neurological Trauma N/A
Withdrawn NCT00262392 - Study of Pamidronate for the Prevention of Heterotopic Ossification N/A
Withdrawn NCT04867018 - Defining the Pathophysiology of Heterotopic Ossification: A Prospective Study
Completed NCT01539447 - Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy Early Phase 1
Completed NCT05218954 - Balance in Patients With Ectopic Bone Tissue After Total Hip Replacement
Completed NCT06251349 - Comparative Analysis of Radiotherapeutic and Medical Procedures for the Prophylaxis of Heterotopic Ossifications
Completed NCT03974698 - Uncemented Hemiarthroplasty, Radiological Features Comparing Lateral Versus Anterolateral Approach N/A
Enrolling by invitation NCT05648916 - Celebrex and HO Study